PPACA

Obamacare reconsidered: a pretty good deal for the drug industry

Obamacare reconsidered: a pretty good deal for the drug industry

By

As the Supreme Court weighs the constitutionality of the Patient Protection and Affordable Care Act's "Individual Mandate"—and maybe the law itself—a pretty sweet deal for the drug industry hangs in the balance.

Email Newsletters

MM&M inVISION